Brodsky J T, Cohen A M
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Dis Colon Rectum. 1991 Aug;34(8):723-7. doi: 10.1007/BF02050360.
Adjuvant therapeutic strategies for colon cancer are based on the knowledge of tumor recurrence patterns following potentially curative resection. Innovative methods for regional delivery of chemotherapy to the liver and peritoneal surfaces are now available to complement systemic treatment. We reviewed clinical, reoperation, and autopsy series to determine the incidence of peritoneal seeding following colon cancer resection. The data suggest a 25-35 percent peritoneal failure rate among patients that recur, indicating that intraperitoneal chemotherapy is a sensible adjuvant approach. The theory behind intraperitoneal chemotherapy and potential complications is discussed. We suggest initiation of clinical trials combining systemic and intraperitoneal chemotherapy.
结肠癌的辅助治疗策略基于潜在根治性切除术后肿瘤复发模式的相关知识。目前已有将化疗药物局部递送至肝脏和腹膜表面的创新方法，以补充全身治疗。我们回顾了临床、再次手术及尸检系列研究，以确定结肠癌切除术后腹膜种植的发生率。数据表明，复发患者中腹膜种植失败率为25%-35%，这表明腹腔内化疗是一种合理的辅助治疗方法。本文讨论了腹腔内化疗的理论及潜在并发症。我们建议启动全身化疗与腹腔内化疗联合应用的临床试验。
